Charles River Laboratories International (CRL) Accumulated Expenses (2009 - 2025)

Charles River Laboratories International's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $270.1 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 50.53% year-over-year to $270.1 million; the TTM figure through Dec 2025 stood at $270.1 million (up 50.53% YoY), while the FY2025 annual figure was $270.1 million, up 50.53% from the prior year.
• Accumulated Expenses was $270.1 million for Q4 2025 at Charles River Laboratories International, roughly flat from $269.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $270.1 million in Q4 2025 to a low of $176.1 million in Q2 2023.
• Historically, Accumulated Expenses has averaged $214.8 million across 5 years, with a median of $210.7 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Accumulated Expenses soared 58.74% in 2021, then decreased 22.51% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $228.8 million in 2021, then retreated by 13.86% to $197.1 million in 2022, then increased by 8.23% to $213.3 million in 2023, then dropped by 15.88% to $179.4 million in 2024, then surged by 50.53% to $270.1 million in 2025.
• The last three Accumulated Expenses figures came in at $270.1 million (Q4 2025), $269.7 million (Q3 2025), and $227.5 million (Q2 2025), per Business Quant data.